{"id":66319,"date":"2026-05-26T14:10:05","date_gmt":"2026-05-26T06:10:05","guid":{"rendered":"https:\/\/flcube.com\/?p=66319"},"modified":"2026-05-26T14:10:05","modified_gmt":"2026-05-26T06:10:05","slug":"zbd-pharmaceutical-secures-marketing-rights-for-teruisis-cd20-targeted-adc-trs005-in-relapsed-refractory-non-hodgkin-lymphoma","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=66319","title":{"rendered":"ZBD Pharmaceutical Secures Marketing Rights for Teruisi&#8217;s CD20-Targeted ADC TRS005 in Relapsed\/Refractory Non-Hodgkin Lymphoma"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Heilongjiang ZBD Pharmaceutical Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/603567:SHA\">SHA: 603567<\/a>) announced a <strong>strategic agent marketing agreement<\/strong> with fellow Chinese pharmaceutical company <strong>Zhejiang Teruisi Pharmaceutical Co., Ltd.<\/strong> for <strong>TRS005<\/strong>, a <strong>Category 1 innovative drug<\/strong> and <strong>CD20-targeted antibody drug conjugate (ADC)<\/strong> under development for the treatment of <strong>relapsed or refractory non-Hodgkin lymphoma (NHL)<\/strong>.<\/p>\n\n\n\n<h2 id=\"h-deal-structure-amp-strategic-rationale\" class=\"wp-block-heading\">Deal Structure &amp; Strategic Rationale<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Parties<\/strong><\/td><td>ZBD Pharmaceutical (marketing agent) \/ Teruisi Pharma (developer)<\/td><\/tr><tr><td><strong>Asset<\/strong><\/td><td>TRS005 \u2013 Category 1 innovative CD20-targeted ADC<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Relapsed or refractory non-Hodgkin lymphoma (NHL)<\/td><\/tr><tr><td><strong>Agreement Type<\/strong><\/td><td>Agent marketing agreement (China market)<\/td><\/tr><tr><td><strong>Development Stage<\/strong><\/td><td>Registrational Phase II (single-arm)<\/td><\/tr><tr><td><strong>Manufacturing Status<\/strong><\/td><td>Commercial-scale PPQ completed<\/td><\/tr><tr><td><strong>Strategic Rationale<\/strong><\/td><td>ZBD leverages commercial infrastructure; Teruisi focuses on clinical development<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">The partnership enables ZBD Pharmaceutical to expand its oncology portfolio with a late-stage innovative asset while allowing Teruisi to maintain focus on clinical development and regulatory strategy.<\/p>\n\n\n\n<h2 id=\"h-drug-profile-amp-development-status\" class=\"wp-block-heading\">Drug Profile &amp; Development Status<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule:<\/strong> <strong>CD20-targeted antibody drug conjugate (ADC)<\/strong> \u2013 Category 1 innovative drug designation<\/li>\n\n\n\n<li><strong>Target:<\/strong> <strong>CD20<\/strong> \u2013 well-validated B-cell marker expressed in most NHL subtypes<\/li>\n\n\n\n<li><strong>Indication:<\/strong> <strong>Relapsed or refractory non-Hodgkin lymphoma (NHL)<\/strong> \u2013 significant unmet medical need<\/li>\n\n\n\n<li><strong>Current Status:<\/strong><\/li>\n\n\n\n<li><strong>Commercial-scale process performance qualification (PPQ) manufacturing completed<\/strong><\/li>\n\n\n\n<li><strong>Single-arm registrational Phase II trial actively enrolling<\/strong><\/li>\n\n\n\n<li><strong>Regulatory Pathway:<\/strong> Category 1 designation provides expedited review and premium pricing opportunities in China<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-clinical-development-strategy\" class=\"wp-block-heading\">Clinical Development Strategy<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Program Element<\/th><th>Details<\/th><\/tr><\/thead><tbody><tr><td><strong>Trial Design<\/strong><\/td><td>Single-arm registrational Phase II<\/td><\/tr><tr><td><strong>Primary Endpoint<\/strong><\/td><td>Objective response rate (ORR) and duration of response (DOR)<\/td><\/tr><tr><td><strong>Patient Population<\/strong><\/td><td>Relapsed or refractory NHL patients who have failed standard therapies<\/td><\/tr><tr><td><strong>Manufacturing Readiness<\/strong><\/td><td>Commercial-scale PPQ completed \u2013 ready for potential launch<\/td><\/tr><tr><td><strong>Regulatory Timeline<\/strong><\/td><td>NDA submission anticipated upon positive Phase II data<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">The completion of commercial-scale PPQ manufacturing represents a significant de-risking milestone, positioning TRS005 for rapid market entry upon successful clinical trial completion and regulatory approval.<\/p>\n\n\n\n<h2 id=\"h-market-impact-amp-competitive-landscape\" class=\"wp-block-heading\">Market Impact &amp; Competitive Landscape<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>NHL Market Opportunity:<\/strong> China&#8217;s NHL market is estimated at \u00a58-12 billion annually, with relapsed\/refractory patients representing approximately 30-40% of cases<\/li>\n\n\n\n<li><strong>CD20-Targeted Therapies:<\/strong> While rituximab biosimilars dominate the market, novel CD20-targeted ADCs offer potential for improved efficacy in difficult-to-treat populations<\/li>\n\n\n\n<li><strong>Competitive Differentiation:<\/strong> As a Category 1 innovative ADC, TRS005 benefits from data exclusivity, premium pricing, and preferential inclusion in national reimbursement negotiations<\/li>\n\n\n\n<li><strong>Commercial Synergy:<\/strong> ZBD Pharmaceutical&#8217;s established hospital sales force and distribution network provide immediate commercial reach across China&#8217;s tier 1-3 cities<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding partnership agreements, clinical development, regulatory approvals, and commercial expectations for TRS005. Actual results may differ due to risks including clinical trial outcomes, regulatory decisions, competitive dynamics, and market adoption.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/603567_20260526_V53I.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 603567_20260526_V53I.\"><\/object><a id=\"wp-block-file--media-fe4b0089-3899-4cb0-a964-7cfaa4e8a89d\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/603567_20260526_V53I.pdf\">603567_20260526_V53I<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/603567_20260526_V53I.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-fe4b0089-3899-4cb0-a964-7cfaa4e8a89d\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Heilongjiang ZBD Pharmaceutical Co., Ltd. (SHA: 603567) announced a strategic agent marketing agreement with fellow&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[35,16,4754,1370,4755],"class_list":["post-66319","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-adc-xdc","tag-cancer","tag-sha-603567","tag-teruisi-pharma","tag-zbd-pharmaceutical"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.6) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>ZBD Pharmaceutical Secures Marketing Rights for Teruisi&#039;s CD20-Targeted ADC TRS005 in Relapsed\/Refractory Non-Hodgkin Lymphoma - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Heilongjiang ZBD Pharmaceutical Co., Ltd. (SHA: 603567) announced a strategic agent marketing agreement with fellow Chinese pharmaceutical company Zhejiang Teruisi Pharmaceutical Co., Ltd. for TRS005, a Category 1 innovative drug and CD20-targeted antibody drug conjugate (ADC) under development for the treatment of relapsed or refractory non-Hodgkin lymphoma (NHL).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=66319\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ZBD Pharmaceutical Secures Marketing Rights for Teruisi&#039;s CD20-Targeted ADC TRS005 in Relapsed\/Refractory Non-Hodgkin Lymphoma\" \/>\n<meta property=\"og:description\" content=\"Heilongjiang ZBD Pharmaceutical Co., Ltd. (SHA: 603567) announced a strategic agent marketing agreement with fellow Chinese pharmaceutical company Zhejiang Teruisi Pharmaceutical Co., Ltd. for TRS005, a Category 1 innovative drug and CD20-targeted antibody drug conjugate (ADC) under development for the treatment of relapsed or refractory non-Hodgkin lymphoma (NHL).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=66319\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-26T06:10:05+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66319#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66319\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"ZBD Pharmaceutical Secures Marketing Rights for Teruisi&#8217;s CD20-Targeted ADC TRS005 in Relapsed\\\/Refractory Non-Hodgkin Lymphoma\",\"datePublished\":\"2026-05-26T06:10:05+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66319\"},\"wordCount\":429,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"ADC \\\/ XDC\",\"Cancer\",\"SHA: 603567\",\"Teruisi Pharma\",\"ZBD Pharmaceutical\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=66319#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66319\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=66319\",\"name\":\"ZBD Pharmaceutical Secures Marketing Rights for Teruisi's CD20-Targeted ADC TRS005 in Relapsed\\\/Refractory Non-Hodgkin Lymphoma - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-05-26T06:10:05+00:00\",\"description\":\"Heilongjiang ZBD Pharmaceutical Co., Ltd. (SHA: 603567) announced a strategic agent marketing agreement with fellow Chinese pharmaceutical company Zhejiang Teruisi Pharmaceutical Co., Ltd. for TRS005, a Category 1 innovative drug and CD20-targeted antibody drug conjugate (ADC) under development for the treatment of relapsed or refractory non-Hodgkin lymphoma (NHL).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66319#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=66319\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66319#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ZBD Pharmaceutical Secures Marketing Rights for Teruisi&#8217;s CD20-Targeted ADC TRS005 in Relapsed\\\/Refractory Non-Hodgkin Lymphoma\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"ZBD Pharmaceutical Secures Marketing Rights for Teruisi's CD20-Targeted ADC TRS005 in Relapsed\/Refractory Non-Hodgkin Lymphoma - Insight, China&#039;s Pharmaceutical Industry","description":"Heilongjiang ZBD Pharmaceutical Co., Ltd. (SHA: 603567) announced a strategic agent marketing agreement with fellow Chinese pharmaceutical company Zhejiang Teruisi Pharmaceutical Co., Ltd. for TRS005, a Category 1 innovative drug and CD20-targeted antibody drug conjugate (ADC) under development for the treatment of relapsed or refractory non-Hodgkin lymphoma (NHL).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=66319","og_locale":"en_US","og_type":"article","og_title":"ZBD Pharmaceutical Secures Marketing Rights for Teruisi's CD20-Targeted ADC TRS005 in Relapsed\/Refractory Non-Hodgkin Lymphoma","og_description":"Heilongjiang ZBD Pharmaceutical Co., Ltd. (SHA: 603567) announced a strategic agent marketing agreement with fellow Chinese pharmaceutical company Zhejiang Teruisi Pharmaceutical Co., Ltd. for TRS005, a Category 1 innovative drug and CD20-targeted antibody drug conjugate (ADC) under development for the treatment of relapsed or refractory non-Hodgkin lymphoma (NHL).","og_url":"https:\/\/flcube.com\/?p=66319","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-05-26T06:10:05+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=66319#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=66319"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"ZBD Pharmaceutical Secures Marketing Rights for Teruisi&#8217;s CD20-Targeted ADC TRS005 in Relapsed\/Refractory Non-Hodgkin Lymphoma","datePublished":"2026-05-26T06:10:05+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=66319"},"wordCount":429,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["ADC \/ XDC","Cancer","SHA: 603567","Teruisi Pharma","ZBD Pharmaceutical"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=66319#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=66319","url":"https:\/\/flcube.com\/?p=66319","name":"ZBD Pharmaceutical Secures Marketing Rights for Teruisi's CD20-Targeted ADC TRS005 in Relapsed\/Refractory Non-Hodgkin Lymphoma - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-05-26T06:10:05+00:00","description":"Heilongjiang ZBD Pharmaceutical Co., Ltd. (SHA: 603567) announced a strategic agent marketing agreement with fellow Chinese pharmaceutical company Zhejiang Teruisi Pharmaceutical Co., Ltd. for TRS005, a Category 1 innovative drug and CD20-targeted antibody drug conjugate (ADC) under development for the treatment of relapsed or refractory non-Hodgkin lymphoma (NHL).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=66319#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=66319"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=66319#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"ZBD Pharmaceutical Secures Marketing Rights for Teruisi&#8217;s CD20-Targeted ADC TRS005 in Relapsed\/Refractory Non-Hodgkin Lymphoma"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66319","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=66319"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66319\/revisions"}],"predecessor-version":[{"id":66321,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66319\/revisions\/66321"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=66319"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=66319"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=66319"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}